Innate Pharma (IPHYF) 18.0600 $IPHYF Selling Innate

New Post Public Reply Private Reply Replies (0) Message Board

May 18, 2015 at 8:12 AM

Innate Pharma (IPHYF) 18.0600 $IPHYF

Selling Innate Short
EP Vantage - at Seeking Alpha - Sat Apr 25, 7:40AM CDT
Ordinarily a $250m up-front payment for a phase I/II asset would seem generous, but when it comes in a bull market and concerns a red-hot immuno-oncology project - Innate Pharma's ( OTCPK:IPHYF ) IPH2201 - some investors might wonder whether the...
AZN: 69.29 (-0.81)

AstraZeneca Inks Multiple Deals, Immuno-Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:43PM CDT
AstraZeneca's (AZN) global biologics research and development arm, MedImmune, inked deals with Innate Pharma, Celgene and Juno related to its anti-PD-L1 immune checkpoint inhibitor, MEDI4736.
AZN: 69.29 (-0.81), JUNO: 43.37 (-1.52), CELG: 115.53 (+0.45)

AstraZeneca and Innate Pharma team up cancer
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 9:51AM CDT

AZN: 69.29 (-0.81)

Innate Pharma and Sanofi collaborate on next generation antibody-drug conjugates using Innate's site-specific conjugation technology
GlobeNewswire - Thu Apr 16, 12:38AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases, today announced that it has entered into a collaboration agreement with Sanofi to apply Innate Pharma's site-specific conjugation technology to the development of new Antibody Drug Conjugates ("ADC"

.

Cutaneous T-Cell Lymphoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 11:05AM CDT
The report "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin potentially resulting in the development of rashes, plaques and tumors. Cutaneous T cell lymphoma (CTCL) has four stages of progression: patch stage, plaque stage, tumor stage, and erythroderma stage. The disease can manifest at any stage and does not necessarily go through an orderly progression. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cutaneous-t-...eport.html
JNJ: 102.30 (+0.47), CYCC: 0.81 (-0.02), NVS: 103.75 (-0.15), KPTI: 24.81 (-2.02)

INNATE PHARMA : DSMB RECOMMENDS CONTINUATION OF EFFIKIR TRIAL WITH TWO ARMS
GlobeNewswire - Thu Mar 26, 1:36AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announces that the Data and Safety Monitoring Board ("DSMB"

completed its fourth assessment of the EffiKIR study and recommended to stop treatment in one arm and continue the trial with the remaining two arms as per protocol.

Innate Pharma (IPHYF) CEO Herve Brailly on Full Year 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Feb 20, 6:50PM CST

INNATE PHARMA: First Phase II trial with IPH2201 open in head and neck cancer
GlobeNewswire - Fri Dec 19, 12:41AM CST
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announced that the first Phase II trial of IPH2201, a first-in-class NKG2A checkpoint inhibitor, was opened at the Charite Comprehensive Cancer Center (CCCC), Berlin, Germany.

INNATE PHARMA announces its 2015 FINANCIAL CALENDAR as well as its participation in upcoming investor conferences
GlobeNewswire - Tue Dec 02, 12:34AM CST
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, announces today its tentative financial calendar for 2015, which is set as follows:

INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE
GlobeNewswire - Tue Sep 16, 11:40AM CDT
-- Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US
ARIA: 8.89 (-0.02)

Innate Pharma SA concludes target enrollment of 150 Acute Myeloid Leukemia patients in EffiKIR trial
M2 - Fri Jul 25, 4:59AM CDT
Biopharmaceutical company Innate Pharma SA (Euronext Paris: FR0010331421) revealed on Thursday that it has completed target enrollment in the EffiKIR trial with 150 Acute Myeloid Leukemia (AML) patients randomised.
BMY: 67.64 (+0.19)

INNATE PHARMA : Completion of target enrollment in the phase II EffiKIR trial
GlobeNewswire - Thu Jul 24, 12:36AM CDT
-- Data on primary efficacy endpoint Leukemia-Free Survival expected end of 2015
BMY: 67.64 (+0.19)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Human Development Fund's Bold Partnership for Growth

An Unusual Alliance with Far-Reaching Implications Every once in a while, a nonprofit steps up with a move that makes even the toughest investors take notice. This isn't some Wall Street ticker talk, sure, but it’s worth turning your chair toward the table. The Human Development Fund (HDF) has penned a strategic deal with the Islamic Development Bank (IsDB), putting its...

Specialty1 Partners: Top Workplaces Triumph in 2026

Employees Crown Specialty1 Partners a Workplace Gem There are only a few things in the business world sweeter than being named a Top Workplace, and flying that banner proudly is exactly what Specialty1 Partners gets to do. Named a winner by the Houston Chronicle in 2026, this recognition is no regular accolade. It's built on the raw honesty that employee surveys provide,...

BMZ's RB-900 E-Bike Battery Shakes Up U.S. Market

A New Ride: BMZ's Strategic Move Look, the e-bike world isn't just pedaling; it's racing ahead, and BMZ Battery Solutions Group is shifting gears. From November 11–12, 2026, the company's going to stir the pot at Micromobility America, introducing its POWER2RIDE RB-900 e-bike battery—a powerhouse eager to make its mark in the U.S. e-bike scene. We're talking real...

Expo 2027 Belgrade Volunteer Rush: A Global Draw

Massive Volunteer Interest for Expo 2027 Belgrade Maybe I’m getting soft, but there’s something about the human spirit rallying around big events that gets me, even after seeing my share of market rollercoasters. Expo 2027 in Belgrade is attracting an army of volunteers—over 19,000 folks hankering to lend a hand from 154 different countries. Yeah, you read that...

When to Restore or Replace Hardwood Floors: Insights

The Challenge of Decision-Making with Old Hardwood Listen up, folks. You know that feeling when you're eyeballing that scuffed-up hardwood floor, pondering if you're looking at a lost cause? Well, before you lift a finger or pull out a crowbar, maybe tune into what Nick Hopkins from Hopkins Floor Company has got to say in HelloNation's latest piece. He breaks it down,...

AI Faces Accountability Trials in Business 2027

Charting the AI Accountability Course In 2027, the corporate AI landscape won't be the Wild West anymore; it's morphing into a structured battlefield where the winners will be those who successfully enforce accountability. The hands-off, carte blanche days of AI are fading fast, and businesses are starting to scrutinize the AI tools they've been throwing money at. "The...

Paratus Energy Lands Petrobras Tender, Ties Finalizing

Seagems Joint Venture Snags Petrobras Contract Let’s dive headfirst into this business update, because this one's got teeth, folks. Petrobras, the big dog in Brazil’s oil arena, has given the green light to Seagems’ bid, a joint venture half-owned by Paratus Energy Services Ltd. The target? A hefty pipe-laying support vessel (PLSV) contract starting in 2028. But...

Mazda Bolsters Los Angeles Schools with $40K Donation

A Surprise for Los Angeles Educators Picture this: you're grinding through another ordinary day at the school, preaching the wonders of math or orchestrating a PE class, when bang, in walks Mazda and the Chargers, handing out checks like Santa on a mission. Happened to four lucky educators in Los Angeles, thanks to Mazda North American Operations and their Southern...

Bankers Brace for Rising Costs, Falling Loan Demand

Tough Roads Ahead for Bankers? Picture this: bankers everywhere are gripping their coffee mugs a little tighter these days. Why? They’re staring down the barrel of rising funding costs, and loan demand looking about as flat as a pancake. IntraFi, a fintech handshake where finance folks swap tales, did a bit of number-crunching, and it's not paintin' a pretty picture....

LG's ASIL D Certification: A Game Changer in Autos

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...